{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:57:34Z","timestamp":1794427054547,"version":"4.9.1"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008992","name":"Yantai University","doi-asserted-by":"publisher","award":["157"],"award-info":[{"award-number":["157"]}],"id":[{"id":"10.13039\/100008992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116373","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:25:38Z","timestamp":1771359938000},"page":"116373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["From innate immunity to precision cancer therapy: the clinical advancement of NK cell therapy"],"prefix":"10.1016","volume":"174","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhe","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116373_bb0005","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA A Cancer JClinicians"},{"key":"10.1016\/j.intimp.2026.116373_bb0010","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394\u2013424. Doi: https:\/\/doi.org\/10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.intimp.2026.116373_bb0015","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209\u201349. Doi: https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.intimp.2026.116373_bb0020","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.116373_bb0025","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J. Clin. 2021;71:7\u201333. Doi: https:\/\/doi.org\/10.3322\/caac.21654.","DOI":"10.3322\/caac.21654"},{"key":"10.1016\/j.intimp.2026.116373_bb0030","doi-asserted-by":"crossref","unstructured":"Liu S, Galat V, Galat4 Y, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J. Hematol. Oncol. 2021;14:7. Doi: https:\/\/doi.org\/10.1186\/s13045-020-01014-w.","DOI":"10.1186\/s13045-020-01014-w"},{"key":"10.1016\/j.intimp.2026.116373_bb0035","doi-asserted-by":"crossref","unstructured":"Meng F, Zhang S, Xie J, et al. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells. J. Hematol. Oncol. 2023;16:62. Doi: https:\/\/doi.org\/10.1186\/s13045-023-01455-z.","DOI":"10.1186\/s13045-023-01455-z"},{"key":"10.1016\/j.intimp.2026.116373_bb0040","doi-asserted-by":"crossref","unstructured":"C\u00f3zar B, Greppi M, Carpentier S, et al. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11:34\u201344. Doi: https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0655.","DOI":"10.1158\/2159-8290.CD-20-0655"},{"key":"10.1016\/j.intimp.2026.116373_bb0045","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","article-title":"Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance","volume":"20","author":"Zheng","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0050","doi-asserted-by":"crossref","unstructured":"Garcia-Chagollan M, Carranza-Torres IE, Carranza-Rosales P, et al. Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment. Technol. Cancer Res. Treat. 2018;17:1533033818764499. Doi: https:\/\/doi.org\/10.1177\/1533033818764499.","DOI":"10.1177\/1533033818764499"},{"key":"10.1016\/j.intimp.2026.116373_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0060","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/cancers13081926","article-title":"Current perspectives on the use of off the shelf CAR-T\/NK cells for the treatment of Cancer","volume":"13","author":"Cutmore","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116373_bb0065","doi-asserted-by":"crossref","unstructured":"Afolabi LO, Afolabi MO, Sani MM, et al. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. Clin & Trans Imm 2021;10:e1286. Doi: https:\/\/doi.org\/10.1002\/cti2.1286.","DOI":"10.1002\/cti2.1286"},{"key":"10.1016\/j.intimp.2026.116373_bb0070","doi-asserted-by":"crossref","unstructured":"Abel AM, Yang C, Thakar MS, et al. Natural killer cells: development, maturation, and clinical utilization. Front. Immunol. 2018;9:1869. Doi: https:\/\/doi.org\/10.3389\/fimmu.2018.01869.","DOI":"10.3389\/fimmu.2018.01869"},{"key":"10.1016\/j.intimp.2026.116373_bb0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.smim.2014.02.008","article-title":"Human natural killer cell development in secondary lymphoid tissues","volume":"26","author":"Freud","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0080","doi-asserted-by":"crossref","unstructured":"Sojka DK, Plougastel-Douglas B, Yang L, et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. eLife 2014;3:e01659. Doi: https:\/\/doi.org\/10.7554\/eLife.01659.","DOI":"10.7554\/eLife.01659"},{"key":"10.1016\/j.intimp.2026.116373_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00360","article-title":"Modeling human natural killer cell development in the era of innate lymphoid cells","volume":"8","author":"Scoville","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00347","article-title":"Natural killer cell distribution and trafficking in human tissues","volume":"3","author":"Carrega","year":"2012","journal-title":"Front Immun"},{"key":"10.1016\/j.intimp.2026.116373_bb0095","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nri3065","article-title":"Organ-specific features of natural killer cells","volume":"11","author":"Shi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.791220","article-title":"Tcf1 sustains the expression of multiple regulators in promoting early natural killer cell development","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.celrep.2017.06.071","article-title":"The transcription factor Tcf1 contributes to Normal NK cell development and function by limiting the expression of granzymes","volume":"20","author":"Jeevan-Raj","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.116373_bb0110","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1021\/acssynbio.2c00017","article-title":"Temporal expression of transcription factor ID2 improves natural killer cell differentiation from human pluripotent stem cells","volume":"11","author":"Jung","year":"2022","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.intimp.2026.116373_bb0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/2159-8290.CD-15-0732","article-title":"STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion","volume":"6","author":"Gotthardt","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.116373_bb0120","doi-asserted-by":"crossref","unstructured":"Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun. 2014;5:4539. Doi: https:\/\/doi.org\/10.1038\/ncomms5539.","DOI":"10.1038\/ncomms5539"},{"key":"10.1016\/j.intimp.2026.116373_bb0125","doi-asserted-by":"crossref","unstructured":"Li Z-Y, Morman RE, Hegermiller E, et al. The transcriptional repressor ID2 supports natural killer cell maturation by controlling TCF1 amplitude. J. Exp. Med. 2021;218:e20202032. Doi: https:\/\/doi.org\/10.1084\/jem.20202032.","DOI":"10.1084\/jem.20202032"},{"key":"10.1016\/j.intimp.2026.116373_bb0130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1074-7613(03)00294-2","article-title":"GATA-3 promotes maturation, IFN-\u03b3 production, and liver-specific homing of NK cells","volume":"19","author":"Samson","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116373_bb0135","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1084\/jem.20090525","article-title":"T-bet\u2013dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow","volume":"206","author":"Jenne","year":"2009","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.intimp.2026.116373_bb0140","doi-asserted-by":"crossref","unstructured":"Jacobs N, Langers, Renoux, et al. Natural killer cells: role in local tumor growth and metastasis. BTT 2012:73. Doi: https:\/\/doi.org\/10.2147\/BTT.S23976.","DOI":"10.2147\/BTT.S23976"},{"key":"10.1016\/j.intimp.2026.116373_bb0145","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1203\/01.PDR.0000156501.55431.20","article-title":"Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections","volume":"57","author":"Dalle","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.intimp.2026.116373_bb0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"Natural killer cell biology: an update and future directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5722","article-title":"Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility","volume":"7","author":"Strauss-Albee","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116373_bb0160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2026.116373_bb0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbcan.2018.01.005","article-title":"Reformation in chimeric antigen receptor based cancer immunotherapy: redirecting natural killer cell","volume":"1869","author":"Lin","year":"2018","journal-title":"Biochimica et Biophysica acta (BBA) - reviews on Cancer"},{"key":"10.1016\/j.intimp.2026.116373_bb0170","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting human natural killer cell subset function revealed cytolytic CD56dim CD16+ NK cells as rapid producers of abundant IFN-\u03b3 on activation","volume":"108","author":"De Maria","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2026.116373_bb0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing Cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0180","doi-asserted-by":"crossref","unstructured":"Li L, Li A, Jin H, et al. Inhibitory receptors and checkpoints on NK cells: implications for cancer immunotherapy. Pathol. Res. Pract. 2024;253:155003. Doi: https:\/\/doi.org\/10.1016\/j.prp.2023.155003.","DOI":"10.1016\/j.prp.2023.155003"},{"key":"10.1016\/j.intimp.2026.116373_bb0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0190","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00069","article-title":"Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells","volume":"4","author":"Hudspeth","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116373_bb0205","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.intimp.2026.116373_bb0210","doi-asserted-by":"crossref","unstructured":"Liang S, Xu K, Niu L, et al. Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. OTT 2017;Volume 10:4273\u201381. Doi: https:\/\/doi.org\/10.2147\/OTT.S139986, OncoTargets Ther..","DOI":"10.2147\/OTT.S139986"},{"key":"10.1016\/j.intimp.2026.116373_bb0215","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.116373_bb0220","doi-asserted-by":"crossref","unstructured":"Petricevic B, Laengle J, Singer J, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients. J. Transl. Med. 2013;11:307. Doi: https:\/\/doi.org\/10.1186\/1479-5876-11-307.","DOI":"10.1186\/1479-5876-11-307"},{"key":"10.1016\/j.intimp.2026.116373_bb0225","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/annonc\/mds612","article-title":"Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines","volume":"24","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.116373_bb0230","doi-asserted-by":"crossref","unstructured":"Schiele P, Kolling S, Rosnev S, et al. Flow cytometric assessment of Fc\u03b3RIIIa-V158F polymorphisms and NK cell mediated ADCC revealed reduced NK cell functionality in colorectal cancer patients. Cells 2024;14:32. Doi: https:\/\/doi.org\/10.3390\/cells14010032.","DOI":"10.3390\/cells14010032"},{"key":"10.1016\/j.intimp.2026.116373_bb0235","doi-asserted-by":"crossref","unstructured":"Zahavi DJ, Erbe R, Zhang Y-W, et al. Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance. Cancer Biol. Ther. 2023;24:2269637. Doi: https:\/\/doi.org\/10.1080\/15384047.2023.2269637.","DOI":"10.1080\/15384047.2023.2269637"},{"key":"10.1016\/j.intimp.2026.116373_bb0240","doi-asserted-by":"crossref","unstructured":"Fan Z, Han D, Fan X, et al. Ovarian cancer treatment and natural killer cell-based immunotherapy. Front. Immunol. 2023;14:1308143. Doi: https:\/\/doi.org\/10.3389\/fimmu.2023.1308143.","DOI":"10.3389\/fimmu.2023.1308143"},{"key":"10.1016\/j.intimp.2026.116373_bb0245","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3892\/mco.2017.1230","article-title":"Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: a case report","volume":"6","author":"Xie","year":"2017","journal-title":"Molecular and Clinical Oncology"},{"key":"10.1016\/j.intimp.2026.116373_bb0250","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.intimp.2026.116373_bb0255","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian Cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.intimp.2026.116373_bb0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14653249.2010.515582","article-title":"A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer","volume":"13","author":"Geller","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2026.116373_bb0265","doi-asserted-by":"crossref","unstructured":"Geller MA, Bendzick LA, Ryan C, et al. Combination therapy with IL-15 superagonist (ALT-803) and PD-1 blockade enhances human NK cell immunotherapy against ovarian cancer. Gynecol. Oncol. 2017;145:19. Doi: https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.060.","DOI":"10.1016\/j.ygyno.2017.03.060"},{"key":"10.1016\/j.intimp.2026.116373_bb0270","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2017.02.028","article-title":"IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer","volume":"145","author":"Felices","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.116373_bb0275","doi-asserted-by":"crossref","unstructured":"Gubbels JA, Felder M, Horibata S, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 2010;9:11. Doi: https:\/\/doi.org\/10.1186\/1476-4598-9-11.","DOI":"10.1186\/1476-4598-9-11"},{"key":"10.1016\/j.intimp.2026.116373_bb0280","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.2001095","article-title":"Ovarian Cancer ascites inhibits transcriptional activation of NK cells partly through CA125","volume":"208","author":"Fraser","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0285","doi-asserted-by":"crossref","unstructured":"Van Vliet AA, Georgoudaki A-M, Raimo M, et al. Adoptive NK cell therapy: a promising treatment prospect for metastatic melanoma. Cancers 2021;13:4722. Doi: https:\/\/doi.org\/10.3390\/cancers13184722.","DOI":"10.3390\/cancers13184722"},{"key":"10.1016\/j.intimp.2026.116373_bb0290","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116373_bb0295","doi-asserted-by":"crossref","unstructured":"Nakamura T, Sato T, Endo R, et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J. Immunother. Cancer 2021;9:e002852. Doi: https:\/\/doi.org\/10.1136\/jitc-2021-002852.","DOI":"10.1136\/jitc-2021-002852"},{"key":"10.1016\/j.intimp.2026.116373_bb0300","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.7150\/thno.18752","article-title":"Exosomes derived from natural killer cells exert therapeutic effect in melanoma","volume":"7","author":"Zhu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.116373_bb0305","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","article-title":"A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer","volume":"59","author":"Iliopoulou","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116373_bb0310","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1111\/1759-7714.14523","article-title":"Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: expanded observations from a phase I\/IIa randomized controlled trial","volume":"13","author":"Park","year":"2022","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.intimp.2026.116373_bb0315","doi-asserted-by":"crossref","unstructured":"Modak S, Le Luduec J-B, Cheung IY, et al. Adoptive immunotherapy with haploidentical natural killer cells and anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: results of a phase I study. Oncoimmunology 2018:e1461305. Doi: https:\/\/doi.org\/10.1080\/2162402X.2018.1461305.","DOI":"10.1080\/2162402X.2018.1461305"},{"key":"10.1016\/j.intimp.2026.116373_bb0320","doi-asserted-by":"crossref","unstructured":"Han J, Chu J, Keung Chan W, et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 2015;5:11483. Doi: https:\/\/doi.org\/10.1038\/srep11483.","DOI":"10.1038\/srep11483"},{"key":"10.1016\/j.intimp.2026.116373_bb0325","doi-asserted-by":"crossref","unstructured":"Wu H, Liu Q, Wang F, et al. Research progress of NK cells in glioblastoma treatment. OTT 2025;Volume 18:87\u2013106. Doi: https:\/\/doi.org\/10.2147\/OTT.S486411.","DOI":"10.2147\/OTT.S486411"},{"key":"10.1016\/j.intimp.2026.116373_bb0330","doi-asserted-by":"crossref","unstructured":"Sakamoto N, Ishikawa T, Kokura S, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J. Transl. Med. 2015;13:277. Doi: https:\/\/doi.org\/10.1186\/s12967-015-0632-8.","DOI":"10.1186\/s12967-015-0632-8"},{"key":"10.1016\/j.intimp.2026.116373_bb0335","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/neuonc\/noaa047","article-title":"Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma","volume":"22","author":"Khatua","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.intimp.2026.116373_bb0340","doi-asserted-by":"crossref","first-page":"eade3341","DOI":"10.1126\/scitranslmed.ade3341","article-title":"Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma","volume":"15","author":"Cichocki","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116373_bb0345","doi-asserted-by":"crossref","unstructured":"Ishikawa T, Okayama T, Sakamoto N, et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer. Intl Journal of Cancer 2018;142:2599\u2013609. Doi: https:\/\/doi.org\/10.1002\/ijc.31285.","DOI":"10.1002\/ijc.31285"},{"key":"10.1016\/j.intimp.2026.116373_bb0350","doi-asserted-by":"crossref","unstructured":"Neviani P, Wise PM, Murtadha M, et al. Natural killer\u2013derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res. 2019;79:1151\u201364. Doi: https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0779.","DOI":"10.1158\/0008-5472.CAN-18-0779"},{"key":"10.1016\/j.intimp.2026.116373_bb0355","doi-asserted-by":"crossref","unstructured":"Han B, Mao F, Zhao Y, et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J. Immunol. Res. 2018;2018:1\u20139. Doi: https:\/\/doi.org\/10.1155\/2018\/6248590.","DOI":"10.1155\/2018\/6248590"},{"key":"10.1016\/j.intimp.2026.116373_bb0360","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 Signaling in immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116373_bb0365","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT Signaling: a double-edged sword of immune regulation and Cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116373_bb0370","doi-asserted-by":"crossref","unstructured":"Boyiadzis M, Agha M, Redner RL, et al. Phase 1 clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy 2017;19:1225\u201332. Doi: https:\/\/doi.org\/10.1016\/j.jcyt.2017.07.008.","DOI":"10.1016\/j.jcyt.2017.07.008"},{"key":"10.1016\/j.intimp.2026.116373_bb0375","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.116373_bb0380","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116373_bb0385","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116373_bb0390","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid Leukemia in vitro with a CD16 \u00d7 33 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116373_bb0395","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116373_bb0400","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.141.10.3478","article-title":"Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes","volume":"141","author":"Lanier","year":"1988","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116373_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116373_bb0410","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2026.116373_bb0415","doi-asserted-by":"crossref","unstructured":"Pesce S, Greppi M, Grossi F, et al. PD\/1-PD-ls checkpoint: insight on the potential role of NK cells. Front. Immunol. 2019;10:1242. Doi: https:\/\/doi.org\/10.3389\/fimmu.2019.01242.","DOI":"10.3389\/fimmu.2019.01242"},{"key":"10.1016\/j.intimp.2026.116373_bb0420","doi-asserted-by":"crossref","unstructured":"Koenig A, Chen C-C, Mar\u00e7ais A, et al. Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. Nat. Commun. 2019;10:5350. Doi: https:\/\/doi.org\/10.1038\/s41467-019-13113-5.","DOI":"10.1038\/s41467-019-13113-5"},{"key":"10.1016\/j.intimp.2026.116373_bb0425","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex vivo\u2013expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2026.116373_bb0430","doi-asserted-by":"crossref","unstructured":"Leivas A, Perez-Martinez A, Blanchard MJ, et al. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology 2016;5:e1250051. Doi: https:\/\/doi.org\/10.1080\/2162402X.2016.1250051.","DOI":"10.1080\/2162402X.2016.1250051"},{"key":"10.1016\/j.intimp.2026.116373_bb0435","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2026.116373_bb0440","doi-asserted-by":"crossref","unstructured":"Casneuf T, Xu XS, Adams HC, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1:2105\u201314. Doi: https:\/\/doi.org\/10.1182\/bloodadvances.2017006866.","DOI":"10.1182\/bloodadvances.2017006866"},{"key":"10.1016\/j.intimp.2026.116373_bb0445","doi-asserted-by":"crossref","unstructured":"Benson DM, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma. Blood 2012;120:4324\u201333. Doi: https:\/\/doi.org\/10.1182\/blood-2012-06-438028.","DOI":"10.1182\/blood-2012-06-438028"},{"key":"10.1016\/j.intimp.2026.116373_bb0450","doi-asserted-by":"crossref","unstructured":"Benson DM, Bakan CE, Zhang S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011;118:6387\u201391. Doi: https:\/\/doi.org\/10.1182\/blood-2011-06-360255.","DOI":"10.1182\/blood-2011-06-360255"},{"key":"10.1016\/j.intimp.2026.116373_bb0455","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.116373_bb0460","doi-asserted-by":"crossref","unstructured":"Leivas A, Valeri A, C\u00f3rdoba L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11:146. Doi: https:\/\/doi.org\/10.1038\/s41408-021-00537-w.","DOI":"10.1038\/s41408-021-00537-w"},{"key":"10.1016\/j.intimp.2026.116373_bb0465","doi-asserted-by":"crossref","unstructured":"Pazina T, James AM, MacFarlane AW, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and \u2013independent mechanisms. Oncoimmunology 2017;6:e1339853. Doi: https:\/\/doi.org\/10.1080\/2162402X.2017.1339853.","DOI":"10.1080\/2162402X.2017.1339853"},{"key":"10.1016\/j.intimp.2026.116373_bb0470","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","article-title":"Enhanced SLAMF7 homotypic interactions by Elotuzumab improves NK cell killing of multiple myeloma","volume":"7","author":"Pazina","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116373_bb0475","doi-asserted-by":"crossref","first-page":"253.e1","DOI":"10.1016\/j.jtct.2022.12.025","article-title":"Phase I study: safety and efficacy of an ex vivo-expanded allogeneic natural killer cell (MG4101) with rituximab for relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"29","author":"Yoon","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.intimp.2026.116373_bb0480","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116373_bb0485","doi-asserted-by":"crossref","unstructured":"Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015;125:4024\u201331. Doi: https:\/\/doi.org\/10.1182\/blood-2014-12-614636.","DOI":"10.1182\/blood-2014-12-614636"},{"key":"10.1016\/j.intimp.2026.116373_bb0490","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/curroncol28020105","article-title":"The advances and challenges of NK cell-based Cancer immunotherapy","volume":"28","author":"Kang","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2026.116373_bb0495","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2026.116373_bb0500","doi-asserted-by":"crossref","unstructured":"Balkhi S, Zuccolotto G, Di Spirito A, et al. CAR-NK cell therapy: promise and challenges in solid tumors. Front. Immunol. 2025;16:1574742. Doi: https:\/\/doi.org\/10.3389\/fimmu.2025.1574742.","DOI":"10.3389\/fimmu.2025.1574742"},{"key":"10.1016\/j.intimp.2026.116373_bb0505","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116373_bb0510","article-title":"Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors","volume":"23","author":"Lian","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.intimp.2026.116373_bb0515","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2026.116373_bb0520","doi-asserted-by":"crossref","unstructured":"Wilkie S, Van Schalkwyk MCI, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 2012;32:1059\u201370. Doi: https:\/\/doi.org\/10.1007\/s10875-012-9689-9.","DOI":"10.1007\/s10875-012-9689-9"},{"key":"10.1016\/j.intimp.2026.116373_bb0525","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"eBioMedicine"},{"key":"10.1016\/j.intimp.2026.116373_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886429","article-title":"Next generation natural killer cells for Cancer immunotherapy","volume":"13","author":"Rossi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0540","doi-asserted-by":"crossref","unstructured":"Depil S, Duchateau P, Grupp SA, et al. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 2020;19:185\u201399. Doi: https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","DOI":"10.1038\/s41573-019-0051-2"},{"key":"10.1016\/j.intimp.2026.116373_bb0545","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575609","article-title":"Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0555","doi-asserted-by":"crossref","unstructured":"Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 2013;31:413\u201341. Doi: https:\/\/doi.org\/10.1146\/annurev-immunol-032712-095951.","DOI":"10.1146\/annurev-immunol-032712-095951"},{"key":"10.1016\/j.intimp.2026.116373_bb0560","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of Intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Kicielinski","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.116373_bb0565","doi-asserted-by":"crossref","unstructured":"Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell 2018;175:1972\u20131988.e16. Doi: https:\/\/doi.org\/10.1016\/j.cell.2018.11.021.","DOI":"10.1016\/j.cell.2018.11.021"},{"key":"10.1016\/j.intimp.2026.116373_bb0570","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1172\/JCI69369","article-title":"Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis","volume":"123","author":"Liu","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116373_bb0575","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116373_bb0580","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.1501783","article-title":"Metabolic reprogramming supports IFN-\u03b3 production by CD56bright NK cells","volume":"196","author":"Keating","year":"2016","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.intimp.2026.116373_bb0585","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1016\/j.apsb.2024.05.032","article-title":"Enhancing cancer immunotherapy: nanotechnology-mediated immunotherapy overcoming immunosuppression","volume":"14","author":"Chen","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2026.116373_bb0590","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.116373_bb0595","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/imm.13094","article-title":"Genetic reprogramming for NK cell cancer immunotherapy with CRISPR\/Cas9","volume":"158","author":"Afolabi","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2026.116373_bb0600","doi-asserted-by":"crossref","unstructured":"Zhao Z, Ding Y, Tran LJ, et al. Innovative breakthroughs facilitated by single-cell multi-omics: manipulating natural killer cell functionality correlates with a novel subcategory of melanoma cells. Front. Immunol. 2023;14:1196892. Doi: https:\/\/doi.org\/10.3389\/fimmu.2023.1196892.","DOI":"10.3389\/fimmu.2023.1196892"},{"key":"10.1016\/j.intimp.2026.116373_bb0605","doi-asserted-by":"crossref","unstructured":"Peng S, Lin A, Jiang A, et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol. Cancer 2024;23:58. Doi: https:\/\/doi.org\/10.1186\/s12943-024-01972-6.","DOI":"10.1186\/s12943-024-01972-6"},{"key":"10.1016\/j.intimp.2026.116373_bb0610","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7150\/jca.101420","article-title":"The cellular signaling crosstalk between memory B cells and tumor cells in nasopharyngeal carcinoma cannot be overlooked: their involvement in tumor progression and treatment strategy is significant","volume":"16","author":"Li","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.intimp.2026.116373_bb0615","doi-asserted-by":"crossref","unstructured":"Zaiatz-Bittencourt V, Jones F, Tosetto M, et al. Butyrate limits human natural killer cell effector function. Sci. Rep. 2023;13:2715. Doi: https:\/\/doi.org\/10.1038\/s41598-023-29731-5.","DOI":"10.1038\/s41598-023-29731-5"},{"key":"10.1016\/j.intimp.2026.116373_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1638352","article-title":"Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies","volume":"16","author":"Tong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0625","doi-asserted-by":"crossref","unstructured":"Chen L, Lin A, Tang B, et al. The future of cancer therapy: nanomaterials and tumor microenvironment. iMetaMed 2025;1:e70007. Doi: https:\/\/doi.org\/10.1002\/imm3.70007.","DOI":"10.1002\/imm3.70007"},{"key":"10.1016\/j.intimp.2026.116373_bb0630","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.cmet.2021.04.002","article-title":"Mechanoresponsive metabolism in cancer cell migration and metastasis","volume":"33","author":"Zanotelli","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.116373_bb0635","doi-asserted-by":"crossref","unstructured":"Tran NA, Moonshi SS, Lam AK, et al. Nanomaterials in cancer starvation therapy: pioneering advances, therapeutic potential, and clinical challenges. Cancer Metastasis Rev. 2025;44:51. Doi: https:\/\/doi.org\/10.1007\/s10555-025-10267-1.","DOI":"10.1007\/s10555-025-10267-1"},{"key":"10.1016\/j.intimp.2026.116373_bb0640","doi-asserted-by":"crossref","unstructured":"Chen L, Hong W, Ren W, et al. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Sig Transduct Target Ther 2021;6:225. Doi: https:\/\/doi.org\/10.1038\/s41392-021-00631-2, Signal Transduct. Target. Ther..","DOI":"10.1038\/s41392-021-00631-2"},{"key":"10.1016\/j.intimp.2026.116373_bb0645","doi-asserted-by":"crossref","unstructured":"Sun R, Xiang J, Zhou Q, et al. The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives. Adv. Drug Deliv. Rev. 2022;191:114614. Doi: https:\/\/doi.org\/10.1016\/j.addr.2022.114614.","DOI":"10.1016\/j.addr.2022.114614"},{"key":"10.1016\/j.intimp.2026.116373_bb0650","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1021\/acs.nanolett.2c02475","article-title":"A Nanounit strategy disrupts energy metabolism and alleviates immunosuppression for Cancer therapy","volume":"22","author":"Luo","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.intimp.2026.116373_bb0655","doi-asserted-by":"crossref","unstructured":"Yang B, Meng F, Zhang J, et al. Engineered drug delivery nanosystems for tumor microenvironment normalization therapy. Nano Today 2023;49:101766. Doi: https:\/\/doi.org\/10.1016\/j.nantod.2023.101766.","DOI":"10.1016\/j.nantod.2023.101766"},{"key":"10.1016\/j.intimp.2026.116373_bb0660","doi-asserted-by":"crossref","unstructured":"Lu Q, Kou D, Lou S, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J. Hematol. Oncol. 2024;17:16. Doi: https:\/\/doi.org\/10.1186\/s13045-024-01535-8.","DOI":"10.1186\/s13045-024-01535-8"},{"key":"10.1016\/j.intimp.2026.116373_bb0665","doi-asserted-by":"crossref","unstructured":"Lin A, Ye P, Li Z, et al. Natural killer cell immune checkpoints and their therapeutic targeting in cancer treatment. Research 2025;8:0723. Doi: 10.34133\/research.0723.","DOI":"10.34133\/research.0723"},{"key":"10.1016\/j.intimp.2026.116373_bb0670","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","article-title":"IGSF8 is an innate immune checkpoint and cancer immunotherapy target","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116373_bb0675","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00262-024-03671-z","article-title":"Characterization of a novel anti-PVRIG antibody with fc-competent function that exerts strong antitumor effects via NK activation in preclinical models","volume":"73","author":"Xue","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116373_bb0680","doi-asserted-by":"crossref","unstructured":"Li J, Whelan S, Kotturi MF, et al. PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia. Haematol. 2020;106:3115\u201324. Doi: https:\/\/doi.org\/10.3324\/haematol.2020.258574.","DOI":"10.3324\/haematol.2020.258574"},{"key":"10.1016\/j.intimp.2026.116373_bb0685","doi-asserted-by":"crossref","unstructured":"Q. Zhang, Prognostic impact of enhanced CD96 expression on NK cells by TGF-\u03b21 in AML, Int. Immunopharmacol.2024 Nov 15;141:112958. doi:10.1016\/j.intimp.2024.112958.","DOI":"10.1016\/j.intimp.2024.112958"},{"key":"10.1016\/j.intimp.2026.116373_bb0690","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/0109298665348639250115113650","article-title":"iRGD tumor penetrating peptide-modified NK cells exhibit enhanced tumor immune infiltration ability and anti-tumor efficacy","volume":"32","author":"Song","year":"2025","journal-title":"Protein & Peptide Letters"},{"key":"10.1016\/j.intimp.2026.116373_bb0695","doi-asserted-by":"crossref","unstructured":"Rozenbaum M, Meir A, Aharony Y, et al. Gamma-Delta CAR-T cells show CAR-directed and independent activity against leukemia. Front. Immunol. 2020;11:1347. Doi: https:\/\/doi.org\/10.3389\/fimmu.2020.01347.","DOI":"10.3389\/fimmu.2020.01347"},{"key":"10.1016\/j.intimp.2026.116373_bb0700","doi-asserted-by":"crossref","unstructured":"Zhi L, Su X, Yin M, et al. Genetical engineering for NK and T cell immunotherapy with CRISPR\/Cas9 technology: implications and challenges. Cell. Immunol. 2021;369:104436. Doi: https:\/\/doi.org\/10.1016\/j.cellimm.2021.104436.","DOI":"10.1016\/j.cellimm.2021.104436"},{"key":"10.1016\/j.intimp.2026.116373_bb0705","doi-asserted-by":"crossref","unstructured":"Sarvaria A, Jawdat D, Madrigal JA, et al. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front. Immunol. 2017;8. Doi: https:\/\/doi.org\/10.3389\/fimmu.2017.00329.","DOI":"10.3389\/fimmu.2017.00329"},{"key":"10.1016\/j.intimp.2026.116373_bb0710","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2026.116373_bb0715","doi-asserted-by":"crossref","unstructured":"Saetersmoen ML, Hammer Q, Valamehr B, et al. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin. Immunopathol. 2019;41:59\u201368. Doi: https:\/\/doi.org\/10.1007\/s00281-018-0721-x.","DOI":"10.1007\/s00281-018-0721-x"},{"key":"10.1016\/j.intimp.2026.116373_bb0720","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for Cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.intimp.2026.116373_bb0725","doi-asserted-by":"crossref","unstructured":"Damodharan SN, Walker KL, Forsberg MH, et al. Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. Cytotherapy 2020;22:450\u20137. Doi: https:\/\/doi.org\/10.1016\/j.jcyt.2020.05.001.","DOI":"10.1016\/j.jcyt.2020.05.001"},{"key":"10.1016\/j.intimp.2026.116373_bb0730","doi-asserted-by":"crossref","unstructured":"Berg M, Lundqvist A, McCoy P, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009;11:341\u201355. Doi: https:\/\/doi.org\/10.1080\/14653240902807034.","DOI":"10.1080\/14653240902807034"},{"key":"10.1016\/j.intimp.2026.116373_bb0735","doi-asserted-by":"crossref","unstructured":"Qi K, Jia D, Zhou S, et al. Cryopreservation of immune cells: recent progress and challenges ahead. Adv. Biol. 2024;8:2400201. Doi: https:\/\/doi.org\/10.1002\/adbi.202400201.","DOI":"10.1002\/adbi.202400201"},{"key":"10.1016\/j.intimp.2026.116373_bb0740","doi-asserted-by":"crossref","unstructured":"Berjis A, Muthumani D, Aguilar OA, et al. Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nat. Commun. 2024;15:3937. Doi: https:\/\/doi.org\/10.1038\/s41467-024-47574-0.","DOI":"10.1038\/s41467-024-47574-0"},{"key":"10.1016\/j.intimp.2026.116373_bb0745","doi-asserted-by":"crossref","unstructured":"Razmara AM, Farley LE, Harris RM, et al. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer. J. Immunother. Cancer 2024;12:e007963. Doi: https:\/\/doi.org\/10.1136\/jitc-2023-007963.","DOI":"10.1136\/jitc-2023-007963"},{"key":"10.1016\/j.intimp.2026.116373_bb0750","doi-asserted-by":"crossref","unstructured":"Terr\u00e9n I, Orrantia A, Vitall\u00e9 J, et al. NK cell metabolism and tumor microenvironment. Front. Immunol. 2019;10:2278. Doi: https:\/\/doi.org\/10.3389\/fimmu.2019.02278.","DOI":"10.3389\/fimmu.2019.02278"},{"key":"10.1016\/j.intimp.2026.116373_bb0755","doi-asserted-by":"crossref","unstructured":"Moinuddin A, Poznanski SM, Portillo AL, et al. Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment. Immunol. Rev. 2024;323:19\u201339. Doi: https:\/\/doi.org\/10.1111\/imr.13316.","DOI":"10.1111\/imr.13316"},{"key":"10.1016\/j.intimp.2026.116373_bb0760","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.tips.2023.08.009","article-title":"Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities","volume":"44","author":"Borde","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2026.116373_bb0765","doi-asserted-by":"crossref","unstructured":"Yang P, Wang W, Liu Q, et al. Metabolic reprogramming of NK cells drives anti-tumor immunity. Crit. Rev. Oncol. Hematol. 2025;215:104859. Doi: https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104859.","DOI":"10.1016\/j.critrevonc.2025.104859"},{"key":"10.1016\/j.intimp.2026.116373_bb0770","doi-asserted-by":"crossref","unstructured":"Jia H, Yang H, Xiong H, et al. NK cell exhaustion in the tumor microenvironment. Front. Immunol. 2023;14:1303605. Doi: https:\/\/doi.org\/10.3389\/fimmu.2023.1303605.","DOI":"10.3389\/fimmu.2023.1303605"},{"key":"10.1016\/j.intimp.2026.116373_bb0775","doi-asserted-by":"crossref","unstructured":"Qiu Z, Li Z, Zhang C, et al. NK cell senescence in cancer: from molecular mechanisms to therapeutic opportunities. Aging Dis. 2025:0. Doi: 10.14336\/AD.2025.0053.","DOI":"10.14336\/AD.2025.0053"},{"key":"10.1016\/j.intimp.2026.116373_bb0780","doi-asserted-by":"crossref","unstructured":"Li JH, Zhou A, Lee CD, et al. MEF2C regulates NK cell effector functions through control of lipid metabolism. Nat. Immunol. 2024;25:778\u201389. Doi: https:\/\/doi.org\/10.1038\/s41590-024-01811-2.","DOI":"10.1038\/s41590-024-01811-2"},{"key":"10.1016\/j.intimp.2026.116373_bb0785","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926002171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:34:29Z","timestamp":1775306069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926002171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":157,"alternative-id":["S1567576926002171"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116373","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From innate immunity to precision cancer therapy: the clinical advancement of NK cell therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116373"}}